SCHEMBL23055144

SCHEMBL23055144

CCC(c1ccc(Cl)cc1)c1ncccc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 4/20 0.45
KCNH2 Q12809 4/20 0.45
CHRM2 P08172 3/20 0.45
ADRA2B P18089 3/20 0.45
SLC6A2 P23975 3/20 0.45
SLC6A4 P31645 3/20 0.45
SLC6A3 Q01959 3/20 0.45
HRH3 Q9Y5N1 3/20 0.45
CHRM1 P11229 3/20 0.45
CYP2D6 P10635 3/20 0.45
CHRM5 P08912 2/20 0.45
HRH2 P25021 2/20 0.45
HTR2A P28223 2/20 0.45
CYP2C9 P11712 1/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
THPO P40225 1/20 0.45
ADRA1A P35348 1/20 0.45
SCN1A P35498 1/20 0.45
HTR2B P41595 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23055173 0.88 CYP17A1 (0.38) HRH1KCNH2CHRM1CYP2D6TSHR
SCHEMBL23589088 0.80 FFAR2 (0.40) HRH1KCNH2CHRM2ADRA2BSLC6A2
SCHEMBL21830982 0.78 NFE2L2 (0.39) TSHRL3MBTL1MEN1KMT2ANFE2L2
SCHEMBL30910888 0.78 NFE2L2 (0.39) TSHRL3MBTL1MEN1KMT2ANFE2L2
SCHEMBL21910140 0.77 FFAR2 (0.41) HRH1KCNH2CHRM2ADRA2BSLC6A2
SCHEMBL21831285 0.76 S1PR3 (0.40) KCNH2MEN1KMT2ALMNANFE2L2
SCHEMBL11736090 0.73 CHRM2 (0.71) HRH1KCNH2CHRM2ADRA2BSLC6A2
SCHEMBL5241824 0.72 ADRB2 (0.48) HRH1KCNH2CHRM2ADRA2BSLC6A2
SCHEMBL469179 0.72 CYP2D6 (0.39) HRH1KCNH2CHRM1CYP2D6CYP2C9
SCHEMBL22040174 0.72 CYP2D6 (0.39) HRH1KCNH2CHRM1CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584747-B2 Substituted pyridopyrimidinonyl compounds useful as T cell activators SYNGENE INTERNATIONAL LIMITED (IN) 2023-02-21 US disclosed
US-20210061802-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS SYNGENE INTERNATIONAL LIMITED (IN) 2021-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584747-B2 Substituted pyridopyrimidinonyl compounds useful as T cell activators DGKZ, DGKA, DGKG HRH1 1601/4885KCNH2 1310/4885CHRM2 2438/4885
US-20210061802-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG HRH1 1601/4885KCNH2 1310/4885CHRM2 2438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.